1. et. al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet
  2. et. al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine 373(1), 23-34.
  3. et. al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine 373(19), 1803-1813.
  4. Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from anadaptive, multiarm, multistage, platform, randomized controlled trial.. Journal of Clinical Oncology 35(14), 1530-1541.
  5. & A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer 49(6), 1287-1296.

See more...


  • PM-317 Genetics of Cancer

    This module will provide students with an advanced understanding about the genetic mechanisms involved in carcinogenesis, and how these underlying processes and molecules affect the human body.


  • Anti-tumour activity of Docetaxel and Biophosphonates in hormone refractory prostate cancer. (awarded 2009)

    Student name:
    Other supervisor: Dr Gianfilippo Bertelli
    Other supervisor: Prof John Wagstaff
  • The use of VES (Vulnerable Elder Survey)-13 screening tool to predict toxicity of chemotherapy in the elderly (awarded 2007)

    Student name:
    Other supervisor: Prof John Wagstaff
    Other supervisor: Professor Robert Leonard